Creating therapeutics to protect kidney function
hero_pattern.png

Nephraegis Therapeutics

Creating solutions
to protect kidney function

 

Why focus on prevention of Acute Kidney Disease (AKI)?


Burden Of Disease

  • Acute Kidney Injury (AKI) is an abrupt loss of kidney function and is a frequent sequela to many types of surgery including common cardiovascular and abdominal procedures

  • Common short-term consequences of AKI include anuria and serious metabolic disorders, often resulting in lengthened ICU stays and in some cases, the need for kidney dialysis and an increased risk of mortality

  • Long-term consequences include chronic kidney disease (CKD), often resulting in ongoing dialysis or transplant and an increased risk of death

  • Current medical response consists of supportive care - no drugs are currently approved to treat AKI

  • Kidney function does not return to baseline in most AKI patients


Incidence of AKI in the United States

  • There are more than 8 million annual cases of AKI in the U.S.alone with more than 80,000 will requiring dialysis

  • Patients who experience AKI following surgery have a greatly increases risk for hospital re-admission and typically spend more days in intensive care following surgery, increasing risk of infection and greatly increasing costs

  • Mortality in patients experiencing AKI has been shown in studies to be as high as 50% in some high-risk populations


Economic Impact of AKI

  • In the United States, annual direct costs of AKI are estimated at $24 billion - and this does not include the costs of dialysis & transplant following End-Stage Renal Disease (ESRD)

  • In the United Kingdom, AKI consumes 1% of the entire NHS budget.

  • Our target AKI market, focused only on easily identified high risk patients currently exceeds $8 billion annually


Nephraegis is Fighting AKI through its development of a family of proprietary drug candidates that have great promise to prevent AKI

  • Lead compound NPH-022 is an epoxyeicosatrienoic-related compound (EET). EETs regulate a variety of renal and vascular processes and hold great promise to treat a variety of kidney diseases

  • NPH-022 has demonstrated an impressive efficacy and safety profile in models of AKI, supporting its potential as a breakthrough candidate to address the unmet medical need in AKI

  • AKI is often debilitating and can greatly decrease quality of live and leads to many premature deaths. Our focus is on improving patients’ lives by preventing AKI


AKI is a high priority for both national and international advocacy groups including the National Kidney Foundation, the American Society for Nephrology and the International Society for Nephrology

 

 
 
The state of care for patients with chronic kidney disease and end-stage renal disease (ESRD) is unacceptable:  too many at-risk patients progress to late-stage kidney failure; the mortality rate is too high; current treatment options are expensive and do not produce an acceptable quality of life; and there are not enough kidneys donated to meet the current demand for transplants.
— 10 July 2019, Executive Order - President of the United States